{"id":82162,"date":"2026-05-14T07:02:10","date_gmt":"2026-05-14T07:02:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/82162\/"},"modified":"2026-05-14T07:02:10","modified_gmt":"2026-05-14T07:02:10","slug":"novo-nordisks-strategic-pivot-gains-traction-as-clinical-data-and-analyst-forecast-align","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/82162\/","title":{"rendered":"Novo Nordisk\u2019s Strategic Pivot Gains Traction as Clinical Data and Analyst Forecast Align"},"content":{"rendered":"

Novo Nordisk divests last cell therapy asset to double down on obesity; new data shows Wegovy\u2019s 28% weight loss, prompting a 52% upside analyst forecast.<\/p>\n

Novo Nordisk has moved to sharpen its identity as a pure-play metabolic powerhouse, offloading the last remnant of its cell therapy ambitions just as clinical and analyst catalysts converge on the obesity franchise. The sale of the Parkinson\u2019s disease programme STEM-PD to Cellular Intelligence on 12 May 2026 closes a repositioning initiated late last year, freeing resources for the main event: Wegovy and its oral sibling semaglutide.<\/p>\n

The timing is no coincidence. A day earlier, at the European Congress on Obesity in Istanbul, the company unveiled data that reinforce Wegovy\u2019s potential well beyond weight loss. A subgroup of early responders to a higher dose of the injectable achieved a 28% reduction in body weight. Separate analyses from the OASIS 4 and STEP UP phase 3 trials showed that 27% of patients on the 7.2?mg high dose lost at least 15% of their body weight within 24 weeks. Among those taking the oral semaglutide pill, early responders recorded an average 21.6% weight loss over 64 weeks \u2014 a figure that underscores the drug\u2019s promise in a market where more than 2?million patients have already adopted the oral variant.<\/p>\n

The evidence also hints at cardiovascular and migraine benefits, extending Wegovy\u2019s narrative from a simple obesity drug to a platform product with multiple therapeutic angles. For investors, the message is clear: Novo Nordisk is not merely defending its GLP-1 turf but expanding the medical case for its lead asset.<\/p>\n

Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n

That message appears to have landed. On 13 May, the day after the data presentations, research firm Hedgeye initiated coverage with an upside forecast of 52% to 117%. The core argument: the US market for oral obesity treatments is set to explode, with Hedgeye projecting 3.6?million monthly prescriptions by the end of 2026. That volume would drive earnings per share to $5.06, well above the consensus estimate of $3.55. The current price-to-earnings multiple of 13.6, against an industry average of 16.8, provides the basis for the catch-up, the analysts contend.<\/p>\n

The stock itself has already shown signs of life, albeit from a depressed base. After closing at \u20ac40.17 on Wednesday \u2014 the day before the congress data went public \u2014 shares added roughly 3% in pre-market trading. The 30-day return stands at about 20%, though the 12-month picture remains deeply negative at minus 31%. Technically, the recovery has lifted the stock above its 50-day moving average of \u20ac33.95, but it still trades below the 200-day line of \u20ac42.43. A sustained close above $47 (roughly \u20ac43.30) would act as a buy signal, with the next target near $54, according to Hedgeye\u2019s technical note.<\/p>\n

Amid the clinical and analyst noise, Novo Nordisk also filed a minor administrative move: two individuals related to the chief financial officer each received 50 B?shares as gifts on 7 May, priced around 294 Danish kroner per share. The transaction, being a non-market gift, carries no immediate trading signal.<\/p>\n

Taken together, the past few days represent a concentrated cascade of positive developments. The Parkinson programme exit removes a distraction, the clinical data strengthen Wegovy\u2019s dossier, and the analyst upgrade provides a valuation anchor. The next catalyst \u2014 US weekly prescription figures for oral semaglutide \u2014 will test whether the real-world adoption matches the bullish thesis. For now, with a 200-day moving average within reach and a fresh product story, Novo Nordisk\u2019s recovery narrative has more than one pillar to stand on.<\/p>\n

Ad<\/p>\n

Novo Nordisk Stock: New Analysis – 14 May<\/p>\n

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Novo Nordisk analysis…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk divests last cell therapy asset to double down on obesity; new data shows Wegovy\u2019s 28% weight…\n","protected":false},"author":2,"featured_media":82163,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[12273,28395,3322,269,12332,13583,3845,272,20814,12878,43804],"class_list":{"0":"post-82162","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-analyst","9":"tag-clinical","10":"tag-data","11":"tag-forecast","12":"tag-gains","13":"tag-nordisks","14":"tag-novo","15":"tag-novo-nordisk","16":"tag-pivot","17":"tag-strategic","18":"tag-traction"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116571651782501331","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/82162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=82162"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/82162\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/82163"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=82162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=82162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=82162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}